beta-Bulnesene is a sesquiterpene hydrocarbon reported in patchouli- and cypriol-type aroma systems, but its standalone literature base is thin. Live sources support its chemical identity and occurrence, including PubChem identity data, database occurrence records in Cyperus scariosus, and a Bengali nagarmotha GC-MS certificate already used in the archive. What is missing is equally important: this research pass did not verify constituent-specific human studies, isolated pharmacology papers, or robust safety datasets, so beta-bulnesene should be treated mainly as a composition and aroma marker with explicit evidence gaps.
Chemical identity and composition
PubChem resolves beta-Bulnesene as CID 12302131 with formula C15H24, InChIKey XUTBNOJXXIWRCB-UHFFFAOYSA-N, and IUPAC name 3,8-dimethyl-5-propan-2-ylidene-2,3,3a,4,6,7-hexahydro-1H-azulene. A live PubChem page snippet surfaced CAS 3772-93-8. In the local archive, Bengali nagarmotha essential oil already records beta-Bulnesene at 0.85%. External occurrence databases also list beta-Bulnesene in Cyperus scariosus rhizome oils at 5.52% and 6.81% in separate entries.
Aroma and practical use
- Use the recorded woody, earthy, sesquiterpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A Bengali nagarmotha GC-MS certificate already used in the archive reported beta-Bulnesene at 0.85% of the analyzed oil.
A Bengali nagarmotha GC-MS certificate already used in the archive reported beta-Bulnesene at 0.85% of the analyzed oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Two sCentInDB cypriol-profile entries for Cyperus scariosus rhizome oil list beta-Bulnesene at 6.81% and 5.52%, reinforcing its role as a recurring sesquiterpene marker in some nagarmotha chemotypes.
Two sCentInDB cypriol-profile entries for Cyperus scariosus rhizome oil list beta-Bulnesene at 6.81% and 5.52%, reinforcing its role as a recurring sesquiterpene marker in some nagarmotha chemotypes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA restriction, human tolerability study, or dermal-limit source was verified for isolated beta-Bulnesene in the reviewed public material.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because direct toxicology and pharmacology data are sparse, benefit or safety copy should stay conservative and composition-focused.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- A live exact-match PubMed search for beta-Bulnesene returned no records in this pass, indicating a sparse direct literature base.
- No human clinical studies, constituent-specific mechanism papers, or isolated bioactivity studies were verified for beta-Bulnesene.
- No IFRA Standard, RIFM fragrance ingredient safety assessment, or Tisserand & Young monograph specific to beta-Bulnesene (CAS 3772-93-8) was located after a dedicated safety-focused search pass; a dermal limit percentage was not invented and dermal_limit_verified remains false.
- Constituent-specific sensitization, phototoxicity, inhalation, and chronic toxicology data were not located in the reviewed public sources.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Some findings lack a directly linked source; treat those entries as unverified research notes.